GlassScriptPhysician profile
Thomas D Godleski
NPI 1235168709
$3,254.52
in general payments reported to CMS, 2019-2025
27 companies · $792 in 2025
The $792 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $136 · 2021: $100 · 2022: $46.95 · 2023: $798 · 2024: $816 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,356 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,356.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $685.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $402.67 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $383.83 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $256.97 | 2021-2025 | |
| Pfizer INC. | $157.53 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $140.92 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $135.88 | 2019-2025 | Shingrix, Arexvy |
| Amgen INC. | $133.51 | 2019-2025 | Otezla, Repatha, Evenity |
| Exact Sciences Corporation | $122.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $115.98 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $97.74 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $68.87 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.47 | 2019-2024 | Xifaxan |
| Dynavax Technologies Corporation | $58.50 | 2023-2024 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.02 | 2019-2023 | Tradjenta, Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $50.43 | 2019-2023 | Livalo, Seglentis |
| Becton, Dickinson and Company | $50.00 | 2023 | Bd Safetyglide |
| Janssen Pharmaceuticals, INC | $43.91 | 2019-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $42.92 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $42.80 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $41.71 | 2025 | |
| Ascensia Diabetes Care US INC. | $21.06 | 2024 | |
| Corcept Therapeutics | $20.61 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $19.84 | 2024 | Inspire |
| Eisai INC. | $16.92 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $15.63 | 2022 | |
| Amarin Pharma, INC. | $14.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Godleski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.